Drug intelligence / Profile preview

ΣΦ-4005

Development stage: Preclinical
Lead developer: Sigmapharm Laboratories
Modality: Small Molecules
Administration: Oral

Overview

ΣΦ-4005 is an internal development code used by Sigmapharm Laboratories for a pharmaceutical candidate in their pipeline. Sigmapharm, a company specializing in generic and specialty pharmaceuticals, lists this code in its regulatory submission tracker for products being prepared for Abbreviated New Drug Application (ANDA) or New Drug Application (NDA) submissions. The specific identity of the drug, including its active pharmaceutical ingredient (API), molecular target, and therapeutic indication, has not been publicly disclosed. The program is characterized by Sigmapharm as having significant barrier-to-entry properties, which may include technical challenges related to formulation, stability, bioavailability, or legal challenges involving patent litigation.

Beyond the preview

Go deeper on ΣΦ-4005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ΣΦ-4005.

Explore the full profile